Category: Joint ventures/collaborations
-
Study to Develop Simple, Standard TBI Test Process
9 March 2016. An industry, academic, and medical center research team is beginning a study to better diagnose traumatic brain injury with multiple testing methods. The project is an undertaking of medical device maker Abbott, Hennepin County Medical Center in Minneapolis, and University of Minnesota medical school, also in Minneapolis. The initiative aims to develop…
-
Gene Editing Creates Pigs Resilient to African Virus
23 February 2016. University and industry researchers edited the genomes of domesticated pigs to create a variety better able to withstand a deadly tick-borne virus. The team from University of Edinburgh and the biotechnology companies Sangamo BioSciences and Genus plc published its findings in yesterday’s (22 February) issue of the journal Scientific Reports. The team…
-
Breast Cancer Academic Research Program Launched
23 February 2016. Breast Cancer Research Foundation in New York began a new initiative to attract more academic researchers to take part in clinical trials of cancer therapies. The group is starting its Drug Research Collaborative, with a $15 million contribution from drug maker Pfizer, that is also granting research access to its cancer drug…
-
Bayer Funding Studies of Honey Bee Health, Management
18 February 2016. Bayer Crop Science is seeking research ideas for improving the health of honey bee colonies in the U.S. Proposals for studies in the $1 million program addressing urgent needs highlighted by Bayer’s Healthy Hives 2020 initiative are due by 1 March 2016. Bees, which play a key role in agriculture, are facing…
-
Antibody Treatment Designed for MERS Virus
18 February 2016. The Middle East respiratory syndrome coronavirus, or MERS virus, is spreading throughout the Middle East and Asia, largely through person-to-person contacts, and with a fatality rate of 36 percent. A research team at University of Maryland, with colleagues from industry and government labs, developed antibodies from genetically-engineered cattle that protect lab mice…
-
Alliance Creating PTSD Knowledge Base
11 February 2016. A collaboration of three organizations and companies in the U.S. and Germany is building an authoritative and systematic collection of research on post-traumatic stress disorder or PTSD. The PTSD KnowledgeMap, as it’s called, is a project of Cohen Veterans Bioscience, Exaptive Inc,. and Fraunhofer Institute for Algorithms and Scientific Computing, and will…
-
Workplace Heart Health Platform in Development
1 February 2016. American Heart Association is developing a technology platform to help people at work track progress toward their wellness goals, and allow companies to evaluate their corporate wellness programs. The platform takes advantage of cloud computing power from the IBM Watson system and connects users through the Web or mobile access. The new…
-
Illumina Providing Genomic Analysis for Precision Medicine
1 February 2016. Illumina Inc., a developer of genetic systems, is analyzing genomic data at four medical centers to integrate with patients’ electric health records for precision medicine. The San Diego company’s analytical services are expected to sequence and characterize the genomes of more than 200,000 individuals in the U.S. and Canada. Medical centers taking…
-
Allergan, AstraZeneca Partner on Drug-Resistant Bacteria
29 January 2016. Pharmaceutical companies Allergan and AstraZeneca are developing a new treatment for infections caused by a type of bacteria already resistant to antibiotics. Financial aspects of the collaboration between the enterprises were not disclosed. The agreement calls for the two companies to develop and commercialize ATM-AVI, a new drug that treats infections from…
-
Business-Academic Coop to Fund Translational Research
25 January 2016. Three pharmaceutical companies and three universities in the U.K. are forming an independent consortium to support academic research leading to new therapies. The £40 million ($US 57 million) Apollo Therapeutics Fund will be financed by contributions from global pharmaceutical enterprises AstraZeneca, GlaxoSmithKline, and Johnson & Johnson, for work in research labs at…